Suppression of neuroinflammation and α-synuclein oligomerization by rotarod walking exercise in subacute MPTP model of Parkinson's disease
暂无分享,去创建一个
Hee-Sun Kim | J. Park | Y. Leem | Jin‐Sun Park | Do-Youn Kim
[1] Hee-Sun Kim,et al. Neurogenic effects of rotarod walking exercise in subventricular zone, subgranular zone, and substantia nigra in MPTP-induced Parkinson’s disease mice , 2022, Scientific Reports.
[2] Hee-Sun Kim,et al. Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson’s Disease Mouse Models , 2022, International journal of molecular sciences.
[3] Y. Vandermeeren,et al. Bimanual motor skill learning with robotics in chronic stroke: comparison between minimally impaired and moderately impaired patients, and healthy individuals , 2021, Journal of NeuroEngineering and Rehabilitation.
[4] P. Tucci,et al. A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases , 2022, Frontiers in Cellular Neuroscience.
[5] Wugang Hou,et al. Sevoflurane preconditioning protects experimental ischemic stroke by enhancing anti‐inflammatory microglia/macrophages phenotype polarization through GSK‐3β/Nrf2 pathway , 2021, CNS neuroscience & therapeutics.
[6] Shin-Da Lee,et al. Effects of Treadmill Exercise on Neural Mitochondrial Functions in Parkinson’s Disease: A Systematic Review of Animal Studies , 2021, Biomedicines.
[7] P. Chiang,et al. Low-Intensity Pulsed Ultrasound Enhances Neurotrophic Factors and Alleviates Neuroinflammation in a Rat Model of Parkinson's Disease. , 2021, Cerebral cortex.
[8] E. Chang,et al. Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease , 2021, Brain and behavior.
[9] Tingting Zheng,et al. Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease , 2021, Neurochemistry International.
[10] Hee-Sun Kim,et al. Papaverine inhibits α-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson's disease. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[11] Yun Yu,et al. Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/ HIF-1α pathway. , 2020, International immunopharmacology.
[12] X. Ye,et al. Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-κB Pathway in Parkinson’s Disease , 2020, Frontiers in Pharmacology.
[13] Hee-Sun Kim,et al. The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson’s disease mouse models , 2019, Journal of Neuroinflammation.
[14] M. McKeown,et al. Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[15] Jia-Da Li,et al. The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases , 2019, Front. Neurosci..
[16] Man Li,et al. AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression , 2019, Journal of Neuroinflammation.
[17] Eyal Oren,et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, The Lancet. Neurology.
[18] J. Winkler,et al. Perturbation Treadmill Training Improves Clinical Characteristics of Gait and Balance in Parkinson's Disease. , 2019, Journal of Parkinson's disease.
[19] Xiaomei Wang,et al. Knockdown of cathepsin D protects dopaminergic neurons against neuroinflammation‐mediated neurotoxicity through inhibition of NF‐κB signalling pathway in Parkinson's disease model , 2019, Clinical and experimental pharmacology & physiology.
[20] Z. Andrews,et al. Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease , 2018, Journal of Parkinson's disease.
[21] Meryem A Yücel,et al. Assessing bimanual motor skills with optical neuroimaging , 2017, Science Advances.
[22] Xia Shen,et al. Long-term effects of exercise and physical therapy in people with Parkinson disease , 2017, Nature Reviews Neurology.
[23] E. Ma,et al. AMPK Maintains Cellular Metabolic Homeostasis through Regulation of Mitochondrial Reactive Oxygen Species. , 2017, Cell reports.
[24] M. Hallett,et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[25] C. Knight,et al. Effects of a low-resistance, interval bicycling intervention in Parkinson’s Disease , 2017, Physiotherapy theory and practice.
[26] Megan Lee,et al. Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review , 2017, PloS one.
[27] Lena H Ting,et al. Increased neuromuscular consistency in gait and balance after partnered, dance-based rehabilitation in Parkinson's disease. , 2017, Journal of neurophysiology.
[28] C. Rapôso,et al. Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model , 2015, Brain Research.
[29] J. Doyon,et al. Enhancing both motor and cognitive functioning in Parkinson’s disease: Aerobic exercise as a rehabilitative intervention , 2015, Brain and Cognition.
[30] G. Knott,et al. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein , 2015, Acta neuropathologica communications.
[31] N. Ibrahim,et al. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. , 2015, Pharmacological research.
[32] J. Goudreau,et al. GSK-3β dysregulation contributes to parkinson’s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein , 2014, Cell Death and Differentiation.
[33] M. Xilouri,et al. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro , 2014, Neurobiology of Disease.
[34] T. Gawlowski,et al. Mitochondrial 8-oxoguanine glycosylase decreases mitochondrial fragmentation and improves mitochondrial function in H9C2 cells under oxidative stress conditions. , 2014, American journal of physiology. Cell physiology.
[35] C. Dobson,et al. Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation , 2013, PloS one.
[36] S. McEwen,et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease , 2013, The Lancet Neurology.
[37] E. Masliah,et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.
[38] G. Deuschl,et al. Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.
[39] D. Hardie,et al. Metabolism of inflammation limited by AMPK and pseudo-starvation , 2013, Nature.
[40] Mu-ming Poo,et al. Neurotrophin regulation of neural circuit development and function , 2012, Nature Reviews Neuroscience.
[41] E. Masliah,et al. The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.
[42] N. Belluardo,et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease , 2012, Cellular and Molecular Life Sciences.
[43] T. Joh,et al. Role of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death* , 2011, The Journal of Biological Chemistry.
[44] A. Sidhu,et al. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia , 2010, Experimental Neurology.
[45] Howard E. Gendelman,et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.
[46] Jiandie D. Lin,et al. Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.
[47] R. Barbour,et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.
[48] Bernardino Ghetti,et al. Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders , 2006, The Journal of Neuroscience.
[49] Kwang-Soo Kim,et al. Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell‐specific manner , 2003, Journal of neurochemistry.
[50] G. Siegel,et al. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain , 2001, Journal of Chemical Neuroanatomy.
[51] Leslie G. Ungerleider,et al. The acquisition of skilled motor performance: fast and slow experience-driven changes in primary motor cortex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.